Beclason ECO Easy Breath compared with a similar freon-containing drug and Flixotide in moderate to severe bronchial asthma patients

Abstract

We tried to evaluate activity of Beclason ECO Easy Breath compared with freon-containing Beclason Easy Breath in patients with moderate to severe bronchia! asthma (BA). A dose of Beclason ECO Easy Breath was chosen considering experimental results and initial clinical trials. Moreover, efficacy of Beclason ECO Easy breath was compared with than of Flixotide in equal doses. The study was two-staged. The 1-st stage was preliminary, the patients were given 1 500 meg of Beclason Easy Breath or 1 000 meg of Flixotide daily to stabilize their status. If the BA became well-controlled after that the patient was transferred to the 2-nd stage which was the study stage. The patients were transferred to the Beclason ECO Easy Breath 1000 meg daily for 3 months. The drug was well tolerated and there were no adverse effects. The BA course was stable. A need in the β₂-agonists reduced in some cases, lung function parameters became higher. Comparing therapeutic doses of Beclason ECO Easy Breath and Flixotide we noted that most the patients demonstrated a growth of spirometric parameters when changing Flixotide 1 000 meg daily to Beclason ECO Easy Breath in the same dose which was apparently provided by regular and long (6 months) use of the basic anti-inflammatory drugs in adequate doses and the breath-activated aerosol delivery device. Some patients needed higher doses of the drug and the ratio of Beclason ECO Easy Breath to Flixotide was 1.5 : 1.